Juno Therapeutics (JUNO) Earns Daily Media Sentiment Rating of 0.24
Media headlines about Juno Therapeutics (NASDAQ:JUNO) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Juno Therapeutics earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 44.0823789151607 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Insider Selling: Juno Therapeutics, Inc. (JUNO) EVP Sells 6,666 Shares of Stock (americanbankingnews.com)
- Juno Therapeutics, Inc. (JUNO) Stock Rating Reaffirmed by Cowen and Company (americanbankingnews.com)
- Juno Therapeutics (JUNO) to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH (streetinsider.com)
- What Juno: Out of ASHes CAR T therapy on the rise, may ‘Transcend’ to leader (bioworld.com)
- Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis (finance.yahoo.com)
JUNO has been the subject of several research analyst reports. BTIG Research upgraded shares of Juno Therapeutics from a “sell” rating to a “neutral” rating in a research note on Monday, August 28th. Zacks Investment Research downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 28th. Wells Fargo & Company restated an “outperform” rating and issued a $54.00 price objective (up previously from $35.00) on shares of Juno Therapeutics in a research note on Tuesday, September 5th. Barclays PLC started coverage on shares of Juno Therapeutics in a research note on Wednesday, September 6th. They issued an “overweight” rating and a $55.00 price objective for the company. Finally, Vetr raised shares of Juno Therapeutics from a “hold” rating to a “buy” rating and set a $28.85 target price for the company in a report on Monday, July 17th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company. Juno Therapeutics presently has an average rating of “Hold” and an average price target of $43.20.
Juno Therapeutics (JUNO) opened at $58.48 on Friday. The company has a quick ratio of 5.08, a current ratio of 4.77 and a debt-to-equity ratio of 0.01.
Juno Therapeutics (NASDAQ:JUNO) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business’s quarterly revenue was up 115.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.57) EPS. equities analysts anticipate that Juno Therapeutics will post -3.53 earnings per share for the current year.
In related news, Director Richard Klausner sold 12,000 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $30.34, for a total transaction of $364,080.00. Following the completion of the transaction, the director now directly owns 788,985 shares in the company, valued at approximately $23,937,804.90. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Robert Azelby sold 6,666 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total transaction of $366,296.70. Following the transaction, the executive vice president now owns 79,998 shares of the company’s stock, valued at $4,395,890.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 91,670 shares of company stock valued at $3,917,857. Corporate insiders own 15.26% of the company’s stock.
WARNING: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/juno-therapeutics-juno-earns-daily-media-sentiment-rating-of-0-24/1677550.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.